Yissum - Research Development Company of the Hebrew University

Novel Therapeutic Target (CD48) for Allergic Conditions (Asthma)

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Diagnostics_ CD48 is involved in chemokine expression and eosinophil recruitment. Therefore, CD48 probably has an important role for orchestrating innate and adaptive responses in allergic lung inflammatory responses.
Inflammation
patent only in US
Babyseed loan Sep 2008 36,000
Nofar application 01/12/13 - with J&J
Project ID : 12-2007-1731

Description of the technology

Anti-CD48 agent blocks CD48 stimulatory pathway and inhibits the activity and expression of CD48

Categories

Drugs, Allergic airway inflammations, Asthma

Development Stage

Laboratory and animal trials were performed

Patent Status

US Granted patent

Market Size

The invention is targeted at the multi-billion fast growing market of drugs for treating asthma and as a diagnostic kit for detection of asthma

Highlights

  • CD48 is a surface-marker molecule present in white blood cells.
  • CD48 was found to be a key molecule in allergic conditions, particularly in allergic airway inflammations like allergic asthma and nasal polyposis.
  • Anti-CD48 agents that block CD48 the stimulatory pathway and inhibit the activity and/or expression of CD48, are excellent candidates for treatment of allergic conditions.
  • CD48 may be secreted by the cell upon cell activation. It is found in the sera of asthmatic patients and can serve as an easy biomarker for disease detection
  • Currently, there is no specific marker for the detection of asthma. The development of a kit using the soluble form of CD48 as the specific marker may provide fast and easy diagnosis tool and an objective evaluation marker of drug treatment effectiveness.

The Innovation

  • The finding that CD48 is a key molecule in allergic airways conditions makes CD48 a possible target molecule in the treatment and diagnosis of allergic airway inflammation such as asthma.
  • The proposed therapy for asthma involves administration of therapeutically effective amounts of an anti-CD48 agent, which blocks CD48 stimulatory pathway and inhibits the activity and/or expression of CD48.
  • Diagnosis using CD48 is based on the determination of CD48 level of expression in serum/plasma and also on white blood cells.

Key Features

The revealing of the role of CD48 in allergic conditions paved the way to using anti-CD48 agents to treat allergic conditions and to using determination of CD48-level as an important and easy to perform diagnostic tool.

Development Milestones

Following the identification of CD48 as an allergen-induced gene in allergic eosinophilic airway inflammation, successful trials in relevant murine models showed that neutralization of CD48 attenuates lung inflammation, goblet cell hyperplasia, mucus production and smooth muscle thickening in the lung – all demonstrating the therapeutic and the diagnostic potentials. Studies with human samples from asthmatic patients have shown significant increase of CD48 in serum[i], eosinophils neutrophils and monocytes .

The Opportunity

Public attention in the developed world has recently focused on asthma because of its rapidly increasing prevalence, affecting up to one in four urban children. For example in the USA 60 million people (1 in 5) suffer from all types of allergies. In addition, in India too the incidence of allergies was found to be very high, (1 in 4).Asthma is the most severe among the chronic allergic diseases since it can eventually lead to death.

Project manager

Shani Bullock
VP, Business Development, Healthcare

Project researchers

Francesca Levi-Schaffer
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Life Science & Biotechnology
  • diagnostics

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.